Less than a year ago, I wrote about the promising results in an Alzheimer’s trial of an infusion called Gammagard. A story on CBSNews.com then reported that the experimental drug had been shown to halt the mental decline in some patients. Admittedly, this was a small study, but the results were exciting.
Unfortunately, an announcement this week has given us a very disappointing update. USAToday.com reports that a larger study shows “…Patients who received infusions with Gammagard fared no better than those given a dummy solution.”